Debuting at BIOCHINA 2026! IMBIORAY’s Off the Shelf NK Cells Demonstrate Industry Leading Strength
- Elva Chen
- 23 hours ago
- 4 min read
On March 12, BIOCHINA 2026 (11th Edition) CBMG BioIndustry Expo opened successfully in Suzhou, where global think tanks gathered to explore development trends in biopharmaceuticals. At this high-profile industry event, iMBioRay made a major appearance with its unique core NK cell technologies and forward looking R&D layout. With strong technological barriers and clinical translation achievements, iMBioRay became one of the highlights of the exhibition.
Decade of Deep Cultivation
IMBIORay Pioneers an Innovative Path for NK Cell Therapy
At this exhibition, iMBioRay not only showcased cutting edge technological achievements but was also invited to deliver two important professional and forward looking speeches. The core technological breakthroughs, clinical research progress and future development paradigm of iMBioRay’s off the shelf NK cell therapy attracted great attention and heated discussion among guests.
Dr. Miao Zhenwei, Chairman and CEO of iMBioRay, was invited to deliver a keynote speech entitled Clinical Research of Antibody NK Cell Conjugate (ACC NK) in Cancer Therapy. Focusing on global clinical pain points in oncology treatment, he deeply interpreted the R&D logic, mechanism of action and clinical progress of ACC NK, a disruptive innovative cell therapy.
Dr. Miao pointed out that traditional NK cell therapy still has room for improvement in tumor targeting and precise killing efficiency. Antibody NK Cell Conjugate (ACC NK) innovatively combines the precise targeting ability of antibodies with the natural killing activity of NK cells, achieving dual breakthroughs in “precise positioning + efficient killing”. It can accurately identify tumor cell targets, greatly improve treatment safety and efficacy, and shows strong clinical potential especially in solid tumor therapy.
Dr. He Xiangfeng, Chief Medical Officer (CMO) of iMBioRay, was invited to give a speech titled iMBioRay’s Off the Shelf NK Cells and New Paradigms for Disease Treatment. Focusing on the core demands of inclusive and large scale development in the cell therapy industry, he comprehensively explained the technological advantages, clinical application scenarios and industry transformation value of off the shelf NK cells.
Dr. He stated that current autologous cell therapy faces problems such as long preparation cycles, poor quality of patients’ own immune cells and high treatment costs, making it difficult to meet large scale clinical popularization needs. Off the shelf NK cells are the core solution to this dilemma.
Independently developed by iMBioRay, off the shelf NK cells rely on a standardized GMP production system to achieve large scale expansion, immune trained culture and standardized preparation of healthy donor cells, enabling “ready to use” therapy that balances efficacy and clinical convenience. Dr. He also shared iMBioRay’s application progress of off the shelf NK cells in autoimmune diseases and other fields with clinical cases, and proposed a new disease treatment paradigm of “off the shelf supply, immediate treatment, universal accessibility”, which completely rewrites the traditional application logic of cell therapy.
Empowered by Cutting Edge Technology
Core Competitive Advantages of iMBioRay NK Cells
Amid increasingly fierce competition in the cell therapy sector, iMBioRay stands out and leads the segment thanks to technological originality, advancement and clinical implementation capabilities. Compared with similar industry products, it has formed four irreplaceable core advantages.
Strong technological originality, disruptively breaking industry bottlenecks
iMBioRay’s independently developed ACC NK antibody cell conjugation technology is a world leading original technology. It integrates antibody targeting with NK cell killing ability, solving industry problems of insufficient targeting and poor solid tumor penetration of traditional NK cells. It boasts excellent clinical data and strong technological barriers.
Outstanding clinical value, wide indication coverage
Supported by the technological advantages of iMBioRay’s off the shelf NK cells, the clinical value is prominent. In clinical trials, it not only shows significant effects on hematologic tumors such as leukemia and lymphoma, but also achieves breakthroughs in solid tumors including lung cancer, liver cancer and breast cancer. It can also be expanded to autoimmune diseases, neurodegenerative diseases and other fields, covering a wide range of indications.
In addition, products in clinical research have shown advantages such as high safety, low adverse reaction rate and good patient tolerance, with strong clinical translation value.
Leading industrialization capability, realizing inclusive implementation
iMBioRay has built a GMP production workshop and completed four technology iterations, realizing a large scale, modular, fully closed and automated NK cell expansion and culture process. It has established a 300 liter ultra large capacity system, with a single batch supporting 200 treatment courses, greatly reducing production costs. It promotes cell therapy from a “niche high end therapy” to a “mass inclusive therapy”, truly bringing cutting edge cell therapy technologies to more ordinary patients.
Anchoring Cutting Edge Innovation
IMBIORay Leads the New Future of Cell Therapy
Currently, the cell therapy industry is at a critical juncture from technological innovation to clinical inclusiveness. Adhering to the core philosophy of “The light of immunotherapy lights up new hope for life”, iMBioRay focuses on a series of off the shelf NK cell therapy products including ACC NK, tiNK and ATE NK. It continues to deepen cutting edge R&D, accelerate clinical pipeline advancement and product commercialization, and is committed to building a world leading NK cell therapy innovation platform.
In the future, iMBioRay will continue to rely on its top R&D team and core technological advantages, actively link upstream and downstream industrial chain resources, deepen clinical cooperation and industrial collaboration, promote clinical translation of more cutting edge cell therapy technologies, solve treatment challenges of more difficult diseases, and bring more efficient, safer and more accessible new treatment solutions to patients worldwide.
Comments